Search - tctmd.com

Displaying 1 - 20 of 83

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Dig Deeper When Dealing With Nonobstructive CAD, AHA Urges

Caitlin E. Cox

November 21, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

Genetic Risk Score for Endothelial Cell Dysfunction Identifies Patients at Risk

News Daily News

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Michael O'Riordan

February 27, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Daily News

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Todd Neale

September 19, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Daily News

LDL Control Remains Poor in CAD Patients: NHANES

Michael O'Riordan

July 05, 2023

News Daily News

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Todd Neale

January 18, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

Advertisement

Year in Review: Top Prevention Stories of 2025

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Dig Deeper When Dealing With Nonobstructive CAD, AHA Urges

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Top General Cardiology and CVD Prevention News of 2023

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

LDL Control Remains Poor in CAD Patients: NHANES

PCSK9 Inhibition Shows Promise for Severe COVID-19 in Pilot Trial

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content